List of investigational anxiolytics

Last updated

This is a dynamic list and may never be able to satisfy particular standards for completeness. You can help by adding missing items with reliable sources.

This is a list of investigational anxiolytics , or anxiolytics that are currently under development for clinical use but are not yet approved. Chemical/generic names are listed first, with developmental code names, synonyms, and brand names in parentheses.

Contents

This list was last comprehensively updated in June 2017. It is likely to become outdated with time.

Generalized anxiety disorder

Panic disorder

Post-traumatic stress disorder

Social anxiety disorder

Others/unspecified

See also

Related Research Articles

<span class="mw-page-title-main">Noradrenergic and specific serotonergic antidepressant</span> Class of antidepressants

Noradrenergic and specific serotonergic antidepressants (NaSSAs) are a class of psychiatric drugs used primarily as antidepressants. They act by antagonizing the α2-adrenergic receptor and certain serotonin receptors such as 5-HT2A and 5-HT2C, but also 5-HT3, 5-HT6, and/or 5-HT7 in some cases. By blocking α2-adrenergic autoreceptors and heteroreceptors, NaSSAs enhance adrenergic and serotonergic neurotransmission in the brain involved in mood regulation, notably 5-HT1A-mediated transmission. In addition, due to their blockade of certain serotonin receptors, serotonergic neurotransmission is not facilitated in unwanted areas, which prevents the incidence of many side effects often associated with selective serotonin reuptake inhibitor (SSRI) antidepressants; hence, in part, the "specific serotonergic" label of NaSSAs.

<span class="mw-page-title-main">Lisuride</span> Chemical compound

Lisuride, sold under the brand name Dopergin among others, is a monoaminergic medication of the ergoline class which is used in the treatment of Parkinson's disease, migraine, and high prolactin levels. It is taken by mouth.

<span class="mw-page-title-main">Serotonin receptor agonist</span> Neurotransmission-modulating substance

A serotonin receptor agonist is an agonist of one or more serotonin receptors. They activate serotonin receptors in a manner similar to that of serotonin, a neurotransmitter and hormone and the endogenous ligand of the serotonin receptors.

<span class="mw-page-title-main">Nemonapride</span> Antipsychotic medication

Nemonapride, also previously known as emonapride and sold under the brand name Emilace, is an atypical antipsychotic which is used in the treatment of schizophrenia. It is taken by mouth.

<span class="mw-page-title-main">UH-301</span> Chemical compound

(S)-UH-301 is a drug and research chemical widely used in scientific studies. It acts as a selective 5-HT1A receptor silent antagonist. It is structurally related to 8-OH-DPAT. UH-301 was found to produce a head-twitch response in mice which is usually typical of 5-HT2A agonist drugs, and has subsequently been used to investigate how 5-HT1A receptor activity modulates 5-HT2A receptors downstream.

<span class="mw-page-title-main">Serotonin antagonist and reuptake inhibitor</span> Class of drug

Serotonin antagonist and reuptake inhibitors (SARIs) are a class of drugs used mainly as antidepressants, but also as anxiolytics and hypnotics. They act by antagonizing serotonin receptors such as 5-HT2A and inhibiting the reuptake of serotonin, norepinephrine, and/or dopamine. Additionally, most also antagonize α1-adrenergic receptors. The majority of the currently marketed SARIs belong to the phenylpiperazine class of compounds.

<span class="mw-page-title-main">Brexpiprazole</span> Atypical antipsychotic

Brexpiprazole, sold under the brand name Rexulti among others, is an atypical antipsychotic medication used for the treatment of major depressive disorder, schizophrenia, and agitation associated with dementia due to Alzheimer's disease.

<span class="mw-page-title-main">Fasedienol</span> Chemical compound

Fasedienol, also known as 4-androstadienol or as 4,16-androstadien-3β-ol, is a pherine which is under development by VistaGen Therapeutics in a nasal spray formulation (PRN) for the acute treatment of social anxiety disorder. It is also being investigated by VistaGen Therapeutics for the treatment of generalized anxiety disorder (GAD) and post-traumatic stress disorder (PTSD). The pherine is a positional isomer of the endogenous pheromone androstadienol. As of 2020, it is in phase III clinical trials for social anxiety disorder.

<span class="mw-page-title-main">Hypidone</span> Investigational antidepressant drug

Hypidone (developmental code name YL-0919) is an investigational serotonergic antidepressant which is under development for the treatment of major depressive disorder. It acts as a serotonin reuptake inhibitor, 5-HT1A receptor partial agonist, and 5-HT6 receptor full agonist. It is used as the hydrochloride salt. As of January 2021, hypidone is in phase 2 clinical trials for major depressive disorder.

<span class="mw-page-title-main">Tebideutorexant</span> Chemical compound

Tebideutorexant (developmental code names JNJ-61393215, JNJ-3215) is an orexin antagonist medication which is under development for the treatment of depression and anxiety disorders. It is an orally active compound and acts as a selective antagonist of the orexin OX1 receptor (1-SORA). Preliminary clinical findings suggest that tebideutorexant may have anti-panic effects in humans. As of June 2023, tebideutorexant is in phase 2 clinical trials for the treatment of major depressive disorder while no further development has been reported for treatment of panic disorder and other anxiety disorders. The drug was originated and developed by Janssen Pharmaceuticals.

References

  1. ↑ "Riluzole sublingual - Biohaven Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  2. ↑ "TGFK 08AA - AdisInsight". adisinsight.springer.com.
  3. 1 2 "FKW 00GA - AdisInsight". adisinsight.springer.com.
  4. ↑ "Darigabat - Cerevel Therapeutics - AdisInsight". adisinsight.springer.com.
  5. 1 2 "JNJ 61393215 - AdisInsight". adisinsight.springer.com.
  6. ↑ "7-Oxoprasterone - Humanetics - AdisInsight". adisinsight.springer.com. Archived from the original on 2017-10-22.
  7. 1 2 Garakani A, Murrough JW, Iosifescu DV (2014). "Advances in Psychopharmacology for Anxiety Disorders". FOCUS. 12 (2): 152–162. doi: 10.1176/appi.focus.12.2.152 . ISSN   1541-4094.
  8. 1 2 Doggrell, S. A. (2007). Novel drugs and products in neuroscience. Drugs of the Future, 32(11), 1007-1017. https://journals.prous.com/journals/servlet/xmlxsl/pk_journals.xml_summary_pr?p_JournalId=2&p_RefId=3853&p_IsPs=Y
  9. 1 2 "BNC 210 - AdisInsight". adisinsight.springer.com.
  10. ↑ "Brexpiprazole - Lundbeck/Otsuka - AdisInsight". adisinsight.springer.com.
  11. ↑ "Iloperidone - Vanda Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  12. ↑ "Methylenedioxymetamfetamine - MAPS Europe B.V. - AdisInsight". adisinsight.springer.com.
  13. ↑ Sessa B (2017). "MDMA and PTSD treatment: "PTSD: From novel pathophysiology to innovative therapeutics"". Neurosci. Lett. 649: 176–180. doi:10.1016/j.neulet.2016.07.004. PMID   27394687. S2CID   3803704.
  14. ↑ Philipps D (29 November 2016). "F.D.A. Agrees to New Trials for Ecstasy as Relief for PTSD Patients". The New York Times. Retrieved 1 June 2017.
  15. ↑ "NBTX 001 - AdisInsight". adisinsight.springer.com.
  16. ↑ "Pomaglumetad methionil - Denovo Biopharma/Eli Lilly and Company - AdisInsight". adisinsight.springer.com.
  17. ↑ "Naloxone/tianeptine - Tonix Pharmaceuticals - AdisInsight". adisinsight.springer.com.
  18. ↑ "Fasedienol - Pherin Pharmaceuticals/VistaGen Therapeutics - AdisInsight". adisinsight.springer.com.
  19. ↑ "JNJ 42165279 - AdisInsight". adisinsight.springer.com. Retrieved 2019-03-02.
  20. ↑ "A Safety and Efficacy Study of JNJ-42165279 in Participants With Social Anxiety Disorder | Clinical Research Trial Listing ( Claustrophobia ) ( NCT02432703 )". www.centerwatch.com. Retrieved 2019-03-02.
  21. ↑ "Etifoxine deuterated - GABA Therapeutics - AdisInsight". adisinsight.springer.com.
  22. ↑ Rupprecht R, Pradhan AK, Kufner M, Brunner LM, Nothdurfter C, Wein S, Schwarzbach J, Puig X, Rupprecht C, Rammes G (December 2022). "Neurosteroids and translocator protein 18 kDa (TSPO) in depression: implications for synaptic plasticity, cognition, and treatment options". Eur Arch Psychiatry Clin Neurosci. 273 (7): 1477–1487. doi:10.1007/s00406-022-01532-3. PMID   36574032. S2CID   255205221.
  23. ↑ "JNJ 42165279 - AdisInsight". adisinsight.springer.com.
  24. ↑ "AVN 101 - AdisInsight". adisinsight.springer.com.
  25. ↑ "Medipure Pharmaceutical MP-20X product line for anxiety". medipurepharmaceuticals. Archived from the original on 2016-10-29.
  26. ↑ "SRX 246 - AdisInsight". adisinsight.springer.com.
  27. ↑ Shri R, Bhutani K, Sharma A (2010). "A new anxiolytic fatty acid from Aethusa cynapium". Fitoterapia. 81 (5): 337–340. doi:10.1016/j.fitote.2010.05.003. PMID   20472038. (https://www.academia.edu/4694323/A_new_anxiolytic_fatty_acid_from_Aethusa_cynapium)
This page is based on this Wikipedia article
Text is available under the CC BY-SA 4.0 license; additional terms may apply.
Images, videos and audio are available under their respective licenses.